Bird Rock Bio, Inc.
http://www.birdrockbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Bird Rock Bio, Inc.
Lilly Adds To Radiopharma Arsenal With Option To Buy Radionetics
Lilly paid $140m up front for an option to acquire Radionetics for $1bn within an undisclosed timeframe. The private firm is developing small molecule GPCR-targeted radiopharmaceuticals.
Deal Watch: Leo Pharma Adds Rare Dermatology Disorder Candidate In Timber Buyout
Plus deals involving SK Biopharmaceuticals, Hikma and Proteovant, Day One/Sprint, Eyenovia/Formosa, Clinigen/CNX, Ikena/Pionyr and more.
Impressive Clinical Results For Argenx’s Oncology Candidate Seal The Deal for Janssen
Janssen boosts its oncology pipeline with argenx’s novel anti-CD70 antibody, which has potential in a variety of indications.
Deals Shaping The Medical Industry, February 2017
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2017
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Anaphore, RuiYi, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice